MARKET

ADMS

ADMS

Adamas Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.09
+0.19
+3.88%
After Hours: 5.09 0 0.00% 16:00 05/14 EDT
OPEN
4.920
PREV CLOSE
4.900
HIGH
5.10
LOW
4.840
VOLUME
412.84K
TURNOVER
--
52 WEEK HIGH
9.15
52 WEEK LOW
2.430
MARKET CAP
231.13M
P/E (TTM)
-2.8425
1D
5D
1M
3M
1Y
5Y
The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026
May 12, 2021 (Financial News Media via COMTEX) -- Palm Beach, FL - May 12, 2021 – Autism spectrum disorder (ASD) represents a group of neurodevelopmental...
Financial News Media · 2d ago
Needham Remains a Hold on Adamas Pharmaceuticals (ADMS)
Needham analyst Serge Belanger maintained a Hold rating on Adamas Pharmaceuticals (ADMS) today. The company's shares closed last Tuesday at $5.41.
SmarterAnalyst · 3d ago
BRIEF-Adamas Pharmaceuticals Reports Q1 Loss Per Share $0.36
reuters.com · 4d ago
Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Misses Revenue Estimates
Zacks.com · 4d ago
Adamas Reports First Quarter 2021 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the first quarter ended March 31, 20...
Business Wire · 4d ago
Adamas Pharmaceuticals Q1 EPS $(0.36) Beats $(0.51) Estimate, Sales $19.30M Miss $20.02M Estimate
Adamas Pharmaceuticals (NASDAQ:ADMS) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.51) by 29.41 percent. This is a 38.98 percent increase over losses of $(0.59) per share
Benzinga · 4d ago
Adamas Pharma EPS beats by $0.10, misses on revenue
Adamas Pharma (ADMS): Q1 GAAP EPS of -$0.36 beats by $0.10.Revenue of $19.31M (+33.4% Y/Y) misses by $0.35M.Press Release
Seekingalpha · 4d ago
Adamas Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 10, 2021 / Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 4:30 PM Eastern Time.
ACCESSWIRE · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADMS. Analyze the recent business situations of Adamas Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADMS stock price target is 9.07 with a high estimate of 14.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 125
Institutional Holdings: 18.54M
% Owned: 40.84%
Shares Outstanding: 45.41M
TypeInstitutionsShares
Increased
21
1.74M
New
10
1.63M
Decreased
17
837.50K
Sold Out
9
1.09M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Lead Director/Independent Director
David Mahoney
Chief Executive Officer/Director
Neil McFarlane
Chief Financial Officer/Chief Accounting Officer
Christopher Prentiss
Other
Adrian Quartel
Other
Vijay Shreedhar
Independent Director
Michael Bigham
Independent Director
Martha Demski
Independent Director
Mardi Dier
Independent Director
William Ericson
Independent Director
Bill Ericson
Independent Director
John MacPhee
Independent Director
Spyridon Papapetropoulos
Independent Director
Anna Richo
No Data
About ADMS
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company’s portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson’s disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer’s type.

Webull offers kinds of Adamas Pharmaceuticals Inc stock information, including NASDAQ:ADMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMS stock methods without spending real money on the virtual paper trading platform.